Is Neogen profitable in 2026?

Neogen posted a large GAAP loss after a $461 million non-cash goodwill impairment disclosed January 2025 tied to the 3M merger. FY2026 adjusted EBITDA guidance is about $175 million on revenue of $857-860 million (raised April 9, 2026), but quarterly revenue has fallen YoY for three straight quarters.

Is Neogen doing layoffs?

Yes. Neogen announced a 10% global headcount reduction on April 11, 2026, as part of restructuring that included divesting its Genomics business to Zoetis and its Cleaners and Disinfectants unit.

Could AI replace Neogen's diagnostics?

Unlikely to replace the core business. Neogen's products are regulated, wet-lab diagnostic consumables (test kits, culture media) requiring certified assays and manufacturing scale. Neogen itself uses AI internally only for supply-chain planning, per its Q3 FY2026 earnings call on June 2, 2026.

Who is Neogen's biggest competitor?

Thermo Fisher Scientific, Bio-Rad Laboratories, and bioMerieux compete directly in food-safety diagnostics, while Zoetis has scale advantage in animal health and is acquiring Neogen's Genomics unit for $160 million, a deal announced April 9, 2026.

Who owns Neogen Corporation?

Neogen is a standalone Nasdaq-listed company (NEOG). It restructured ownership on September 1, 2022, via a Reverse Morris Trust merger with 3M's Food Safety Division worth about $5.3 billion, giving 3M shareholders roughly 50.1% of combined shares.

Why did Neogen's stock crash?

Neogen disclosed a $461 million goodwill impairment in January 2025 tied to its botched 3M Food Safety integration, CEO John Adent departed in early 2025, and a securities fraud class action followed; the stock's 52-week range was $4.56 to $11.43 as of July 24, 2026.

Biotech tools companies · United States

Neogen Corporation

neogen.com ↗

Maker of food safety and animal health diagnostic tests, kits, and lab instruments.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from November 2026 · Every call on the record Checkpoint: Targeted close of Zoetis Genomics unit sale, expected to bring in about $140M for debt paydown

The call

Neogen's core testing business still grows, but debt, a shrinking Animal Safety unit, and unresolved litigation are the things actually squeezing the company right now, not AI.

Neogen sells lab tests and equipment that help companies check if their food is safe, which is work that requires certification and has built-in repeat customers. The real competitors like Thermo Fisher and Bio-Rad have broader product lines and deeper pockets, while Neogen is stretched thin after overpaying $5.3 billion to buy 3M's food safety business; the company is now selling pieces of itself to pay down debt and facing lawsuits from angry shareholders. The main question is whether Neogen can sell its animal genetics unit to Zoetis for $140 million by late 2026 and use that money to get its debt under control, because if that deal slips or the money doesn't arrive, the company will stay financially weak and stock holders won't see gains for years.

Why

AI pressure: None apparent. Testing still needs physical assays and lab hardware; AI shows up as data software layered on top, not a replacement for the tests themselves. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher Scientific and Bio-Rad Laboratories. Both already sell competing food-safety diagnostic platforms with far larger balance sheets and sales forces than Neogen. Could a giant copy it? Probably.

What protects it. Labs and food plants already run on Neogen's certified assays and consumables, and swapping validated test workflows out is slow and costly.

What would change this call

Zoetis Genomics divestiture closes near Nov 2026 with ~$140M net proceeds. Shows Neogen can execute deleveraging and shed non-core assets as planned.
Animal Safety segment YoY revenue trend in Q4 FY26 and Q1 FY27 earnings. Reveals whether supplier disruptions ended or customer losses in Animal Safety are structural.
Net debt/EBITDA ratio reported at fiscal year-end May 2026 and calendar year-end 2026. Confirms whether deleveraging below 3x is on track or balance-sheet stress persists.

Key numbers

Q3 FY2026 revenue $211.2M, down 4.4% YoY (2026-02-28)
Animal Safety segment revenue down 20.1% YoY (2026-02-28)
FY2026 revenue guidance cut to $857-860M (2026-04-09)

Named risks

Active securities fraud class action over misleading 3M integration statements (case 1:25-cv-00802). Severity: high
Net debt above 3x EBITDA pending Genomics divestiture proceeds to deleverage. Severity: high
Animal Safety segment down 20.1% YoY in Q3 FY2026 from unresolved third-party supplier issues. Severity: medium
Total revenue declining YoY for multiple consecutive quarters despite Food Safety core growth. Severity: medium
Zoetis Genomics deal could face closing delays, jeopardizing 2026 deleveraging target. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Zoetis	gaining on	Acquiring Neogen's Genomics business for $160M, deal announced 2026-04-09
Thermo Fisher Scientific	contesting	Direct competitor in food-safety diagnostics assays as of 2026
Bio-Rad Laboratories	contesting	Direct competitor in food-safety diagnostics as of 2026
bioMerieux	contesting	Direct competitor in food-safety diagnostics as of 2026
IDEXX Laboratories	gaining on	Larger-scale leader in veterinary diagnostics market Neogen also serves

Questions people ask

Is Neogen profitable in 2026?: Neogen posted a large GAAP loss after a $461 million non-cash goodwill impairment disclosed January 2025 tied to the 3M merger. FY2026 adjusted EBITDA guidance is about $175 million on revenue of $857-860 million (raised April 9, 2026), but quarterly revenue has fallen YoY for three straight quarters.
Is Neogen doing layoffs?: Yes. Neogen announced a 10% global headcount reduction on April 11, 2026, as part of restructuring that included divesting its Genomics business to Zoetis and its Cleaners and Disinfectants unit.
Could AI replace Neogen's diagnostics?: Unlikely to replace the core business. Neogen's products are regulated, wet-lab diagnostic consumables (test kits, culture media) requiring certified assays and manufacturing scale. Neogen itself uses AI internally only for supply-chain planning, per its Q3 FY2026 earnings call on June 2, 2026.
Who is Neogen's biggest competitor?: Thermo Fisher Scientific, Bio-Rad Laboratories, and bioMerieux compete directly in food-safety diagnostics, while Zoetis has scale advantage in animal health and is acquiring Neogen's Genomics unit for $160 million, a deal announced April 9, 2026.
Who owns Neogen Corporation?: Neogen is a standalone Nasdaq-listed company (NEOG). It restructured ownership on September 1, 2022, via a Reverse Morris Trust merger with 3M's Food Safety Division worth about $5.3 billion, giving 3M shareholders roughly 50.1% of combined shares.
Why did Neogen's stock crash?: Neogen disclosed a $461 million goodwill impairment in January 2025 tied to its botched 3M Food Safety integration, CEO John Adent departed in early 2025, and a securities fraud class action followed; the stock's 52-week range was $4.56 to $11.43 as of July 24, 2026.

Timeline

2026-04-11Announced 10% global headcount cut alongside portfolio restructuring
2026-04-09Q3 FY2026 results: revenue $211.2M (-4.4% YoY), raised FY26 guidance, Zoetis Genomics deal announced
2026-02-28Fiscal Q3 2026 period end: Animal Safety segment revenue down 20.1% YoY on supplier issues
2026-01-08Q2 FY2026 results: revenue $224.7M, down 2.8% YoY, core growth +2.9%
2026-01-05Neogen announced two senior leadership appointments (CCO and SVP Global Food Safety)
2025-08-31Q1 FY2026 results: revenue $209.2M, down 3.6% YoY
2025-07-18Grant & Eisenhofer filed securities fraud class action against Neogen
2025-01Disclosed $461 million goodwill impairment; CEO John Adent departed
2022-09-01Completed $5.3 billion Reverse Morris Trust merger with 3M's Food Safety Division

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation